Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on mRNA cell therapies for autoimmune diseases, has granted inducement awards to seven new employees. The company issued options to purchase a total of 100,457 shares of common stock at an exercise price of $15.47 per share, matching the closing price on Nasdaq on August 1, 2024. These options, approved by the board of directors, were granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan. The vesting schedule is 25% on August 1, 2025, followed by three equal annual installments, with full vesting by August 1, 2028. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Cartesian Therapeutics (NASDAQ: RNAC), una società biotecnologica in fase clinica focalizzata su terapie cellulari mRNA per le malattie autoimmuni, ha concesso premi di indennità a sette nuovi dipendenti. L'azienda ha emesso opzioni per acquistare un totale di 100.457 azioni di azioni ordinarie a un prezzo di esercizio di $15,47 per azione, corrispondente al prezzo di chiusura su Nasdaq del 1° agosto 2024. Queste opzioni, approvate dal consiglio di amministrazione, sono state concesse nell'ambito del Piano di Indennità per l'Occupazione Modificato e Ripristinato del 2018. Il programma di maturazione prevede il 25% il 1° agosto 2025, seguito da tre rate annuali uguali, con maturazione completa entro il 1° agosto 2028. Le opzioni hanno un termine di dieci anni e sono state concesse ai sensi della Regola di Quotazione Nasdaq 5635(c)(4) come incentivo all'occupazione.
Cartesian Therapeutics (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica centrada en terapias celulares de mRNA para enfermedades autoinmunitarias, ha otorgado premios de inducción a siete nuevos empleados. La compañía emitió opciones para comprar un total de 100,457 acciones ordinarias a un precio de ejercicio de $15.47 por acción, igual al precio de cierre en Nasdaq del 1 de agosto de 2024. Estas opciones, aprobadas por la junta directiva, se otorgaron bajo el Plan de Incentivos por Inducción al Empleo Modificado y Restablecido de 2018. El cronograma de adquisición es del 25% el 1 de agosto de 2025, seguido de tres pagos anuales iguales, con adquisición total para el 1 de agosto de 2028. Las opciones tienen un plazo de diez años y se otorgaron bajo la Regla de Listado 5635(c)(4) de Nasdaq como incentivo de empleo.
Cartesian Therapeutics (NASDAQ: RNAC)는 자가면역 질환을 위한 mRNA 세포 치료제에 집중하는 임상 단계의 생명공학 회사로, 새로운 직원 7명에게 유인 보상을 부여했습니다. 이 회사는 100,457주의 보통주를 $15.47의 행사 가격으로 구매할 수 있는 옵션을 발행하였으며, 이는 2024년 8월 1일 Nasdaq의 종가에 해당합니다. 이 옵션은 이사회에 의해 승인되었으며, 회사의 개정된 2018년 고용 유인 인센티브 수여 계획에 따라 부여되었습니다. 이옵션의 기준 일정은 2025년 8월 1일에 25%, 그 후 3회의 동등한 연간 할부로 이루어지며, 2028년 8월 1일까지 완전한 권리가 부여됩니다. 이 옵션은 10년의 기간을 가지며, 고용 유인을 위한 Nasdaq 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Cartesian Therapeutics (NASDAQ: RNAC), une entreprise biopharmaceutique en phase clinique axée sur les thérapies cellulaires à base d'ARNm pour les maladies auto-immunes, a accordé des primes d'incitation à sept nouveaux employés. La société a émis des options pour acquérir un total de 100.457 actions ordinaires à un prix d'exercice de $15,47 par action, correspondant au prix de clôture sur le Nasdaq du 1er août 2024. Ces options, approuvées par le conseil d'administration, ont été accordées dans le cadre du Plan de prime d'incitation à l'emploi modifié et rétabli de 2018. Le calendrier d'acquisition prévoit 25% le 1er août 2025, suivi de trois versements annuels égaux, avec pleine acquisition d'ici le 1er août 2028. Les options ont une durée de dix ans et ont été octroyées en vertu de la règle de cotation 5635(c)(4) du Nasdaq en tant qu'incitation à l'emploi.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mRNA-Zelltherapien zur Behandlung von Autoimmunerkrankungen konzentriert, hat sieben neuen Mitarbeitern Anreizvergütungen gewährt. Das Unternehmen gab Optionen zum Kauf von insgesamt 100.457 Aktien mit einem Ausübungspreis von $15,47 pro Aktie aus, was dem Schlusskurs an der Nasdaq am 1. August 2024 entspricht. Diese Optionen, die vom Vorstand genehmigt wurden, wurden im Rahmen des überarbeiteten und wiederhergestellten Anreizplans für Mitarbeiter von 2018 gewährt. Der Vesting-Zeitplan sieht 25% am 1. August 2025 vor, gefolgt von drei gleichen jährlichen Raten, mit vollständiger Ausübung bis zum 1. August 2028. Die Optionen haben eine Laufzeit von zehn Jahren und wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz zur Beschäftigung gewährt.
- Attraction of new talent with stock options as incentives
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to seven new employees. On August 1, 2024, the Company issued to these employees options to purchase an aggregate of 100,457 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Investor Contact
Ron Moldaver
Senior Director, Investor Relations & Business Development
ron.moldaver@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
How many new employees received stock options from Cartesian Therapeutics (RNAC) on August 1, 2024?
What is the exercise price of the stock options granted by Cartesian Therapeutics (RNAC) on August 1, 2024?
When will the stock options granted by Cartesian Therapeutics (RNAC) on August 1, 2024, be fully vested?
What is the total number of shares that can be purchased with the options granted by Cartesian Therapeutics (RNAC) on August 1, 2024?
